CD8+ T Cell Exhaustion and Tumor Immune Checkpoint Blockade: Mechanisms, Heterogeneity, and Combination Intervention Strategies
Gang Liu
Advances in World Medical Research ›› 2026, Vol. 2 ›› Issue (3) : 96 -104.
CD8+ T cells are the core effector cells in anti-tumor immunity, but under continuous tumor antigen stimulation and inhibitory microenvironment, they gradually enter a state of dysfunction, showing reduced effector secretion, decreased proliferation, persistent expression of inhibitory receptors, and abnormal metabolic adaptation, which are driven by a unified transcriptional, epigenetic, metabolic, and microenvironmental exhaustion program. T cell exhaustion is a major reason why immune checkpoint blockade (ICB) therapy has limited effectiveness and also a key target for combination treatment strategies. In recent years, single-cell sequencing, spatial transcriptomics, and functional immunology studies have shown that exhausted T cells are not a single state-they include heterogeneous subgroups such as progenitor exhausted T cells (Tpex), intermediate exhausted T cells, and terminal exhausted T cells. Blocking PD-1/PD-L1 and CTLA-4 can partly restore T cell function, but primary and secondary resistance are still common. This article reviews the unified mechanisms of CD8+ T cell exhaustion and, organized around the axis of 'mechanism-heterogeneity-ICB response-combination strategies', explores potential strategies for immune checkpoint blockade related to CD8+ T cell exhaustion, and also discusses biomarkers and future research directions.
CD8+ T Cells / T Cell Exhaustion / Immune Checkpoint Blockade / Tumor Microenvironment / Immunotherapy
| [1] |
|
| [2] |
|
| [3] |
|
| [4] |
|
| [5] |
|
| [6] |
|
| [7] |
|
| [8] |
|
| [9] |
|
| [10] |
|
| [11] |
|
| [12] |
|
| [13] |
|
| [14] |
|
| [15] |
|
| [16] |
|
| [17] |
|
| [18] |
|
| [19] |
|
| [20] |
|
| [21] |
|
| [22] |
|
| [23] |
|
| [24] |
|
/
| 〈 |
|
〉 |